HLA B Leader in Patients With Psoriatic Arthritis

Centre Hospitalier Universitaire, Amiens658 enrolled

Overview

Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule. Given this association, these diseases are classically regarded as disorders of adaptive immunity. In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

658

Conditions

Psoriatic Arthritis HLA b Leader HLA B27

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * For the "Patient" group: * Patient over 18 years of age * Patient affiliated to a social security scheme * Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie. * For the "control" group: * Individuals over 18 years of age * Individual affiliated to a social security scheme * Individual having agreed to participate in the study * Individuals with no inflammatory or autoimmune diseases Exclusion Criteria: * Patient or control not understanding French * Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort. * Patient or control objecting to participation in the study

Outcomes

Primary Outcomes

prevalence of HLA B leader in both groups

prevalence of HLA B leader in patients with psoriatic rheumatism compared to the healthy group by autoimmune disease

Time frame: 1 year

Secondary Outcomes

Prevalence of HLAB27 gene in both groups

Prevalence of HLAB27 gene in patients with psoriatic rheumatism compared to the healthy group free from autoimmune disease

Time frame: 1 year

prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism patient group

prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism in patients with different disease conditions

Time frame: 1 year

HLA B Leader in Patients With Psoriatic Arthritis

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts